LIMERICK, Pa.--(BUSINESS WIRE)--Apr. 29, 2013--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
devices for critical care and surgery, has announced the first insertion
of the new ARROW® JACC™ Catheter with Chlorag+ard®
Technology.
The ARROW JACC (Jugular Axillo-subclavian Central Catheter) Catheter
with Chlorag+ard Technology is a long-term, small bore
antimicrobial and antithrombogenic catheter that gives clinicians a
single, less-invasive option for critically ill patients for the
duration of their therapy. This catheter, which received FDA clearance
in November 2012, is designed specifically for the non-physician,
Vascular Access Specialist.
The placing of central venous catheters by non-physician inserters is an
emerging trend within healthcare. These Vascular Specialists are driving
best practices such as the use of antimicrobial catheters, ultrasound
and maximal barrier precautions to offset the high-demand and workload
of physicians, who have traditionally placed central lines. To date,
Teleflex Incorporated and its ARROW® Vascular Division have
supported clinicians in expanding their scope of practice to include
central venous catheter insertion in more than forty states.
“The ARROW JACC Catheter with Chlorag+ard Technology has been
designed because every patient deserves the right to zero
complications,” states Paul Molloy, President of the Vascular Division.
“The ARROWJACC Catheter is another example of how we
continue to innovate and bring products to market that satisfy clinical
needs as well as facilitate positive changes we see emerging in the
vascular access space.”
The ARROW JACC Catheter employs Chlorag+ard Technology as a
weapon against infection and thrombosis for up to 30 days. Approximately
80,000 ICU catheter-related bloodstream infections occur each year in
the United States resulting in an estimated 28,000 deaths at a cost of
$2.3 billion.1 The ARROW JACC Catheter with Chlorag+ard
Technology will enable caregivers to effectively and economically care
for millions of critically ill patients.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a
range of procedures in critical care and surgery. Our mission is to
provide solutions that enable healthcare providers to improve outcomes
and enhance patient and provider safety. Headquartered in Limerick, PA,
Teleflex employs approximately 11,600 people worldwide and serves
healthcare providers in more than 140 countries. Additional information
about Teleflex can be obtained from the company's website at teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, Arrow, Chlorag+ard and JACC are
trademarks or registered trademarks of Teleflex Incorporated or its
affiliates.
© 2013 Teleflex Incorporated. All rights reserved. 2013-1999
1. Pronovost P, Needham D, Berenholtz S, et al. An intervention to
decrease catheter-related bloodstream infections in the ICU. N Engl J
Med 2006;355(26):2725.
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836